Vascular Stents Market By Type of Product, Coating, End-User, & Region for 2024-2031

Vascular Stents Market Valuation - 2024-2031

The increasing prevalence of cardiovascular disease is related to aging populations, sedentary lifestyles, and bad diets. New stent technologies, including as drug-eluting and bioresorbable stents, are improving treatment outcomes is fuelling the USD 9.38 Billion in 2024 and reachingUSD 14.36 Billion by 2031.

Furthermore, the increased number of minimally invasive operations, combined with improved healthcare infrastructure and access to innovative medical technologies, especially in emerging regions, is propelling market expansion. Favorable reimbursement policies and increased awareness of vascular health are also driving market growth is fueling market expected to grow at aCAGR of about 5.47% from 2024 to 2031.

Vascular Stents Market: Definition/ Overview

Vascular stents are small, mesh-like medical devices that open and support restricted or obstructed blood arteries, ensuring normal blood flow in the treatment of cardiovascular disease. They are generally utilized in angioplasty operations to treat disorders such as coronary artery disease, peripheral artery disease, and aneurysms by keeping arteries open and lowering the risk of future blockage. The future of vascular stents is in the development of bioresorbable stents, drug-eluting stents, and improved coatings that improve patient outcomes, reduce problems, and provide long-term advantages. Innovations in minimally invasive procedures, as well as increased acceptance in emerging economies, are likely to fuel future growth in this sector.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will Rising Prevalence of Cardiovascular Diseases Propel the Vascular Stents Market?

The global burden of cardiovascular diseases (CVDs) continues to rise, increasing need for effective treatment alternatives such as vascular stents. According to the World Health Organization, CVDs are still the largest cause of death globally, accounting for an estimated 31% of all fatalities. The Centers for Disease Control and Prevention revealed that approximately 655,000 Americans die each year as a result of heart disease.

In April 2024, the US Centers for Disease Control and Prevention (CDC) prioritized cardiovascular health in its public health programs, devoting greater funds to research and improving access to innovative treatments such as vascular stents. These efforts, together with an expanding patient pool and technological improvements, are propelling the market forward and fulfilling rising global demand for stenting treatments.

Will Rising Risk of Stent Thrombosis Complications Hinder the Growth of the Vascular Stents Market?

The increasing risk of stent thrombosis problems is a significant challenge that may impede the growth of the vascular stents market. Stent thrombosis, a disorder in which blood clots form on the stent, can result in major problems, including heart attacks and even death. This danger raises concerns among healthcare practitioners and patients, potentially decreasing stent use, particularly in high-risk groups. As a result, healthcare providers may seek other therapies or place a higher emphasis on post-operative drug adherence to reduce risk, thereby slowing market growth.

Additionally, in reaction to these safety concerns, the regulatory landscape may tighten, resulting in more stringent testing and approval processes for stent technology. Manufacturers may face additional pressure to create more advanced stents that minimize the risk of thrombosis, thereby increasing R&D expenditures and delaying new product introductions. Overall, while stents remain important in cardiovascular treatment, increased knowledge and danger of thrombosis problems may limit market growth unless innovations in stent design effectively address these concerns.

Category-Wise Acumens

Will Increasing Usage of Coronary Stents Propel the Vascular Stents Market?

The increasing use of coronary stents is predicted to greatly boost the vascular stents market. Coronary stents are critical in treating coronary artery disease, which is still a significant cause of death worldwide. The rising prevalence of heart-related illnesses, combined with the expanding use of minimally invasive procedures that use these stents to restore blood flow in clogged arteries, is driving up demand for coronary stents. Furthermore, in April 2024, the European Union increased financing for cardiovascular research, with an emphasis on improving therapeutic technology such as coronary stents. These advancements are driving innovation and fueling market expansion, especially as more patients need stenting treatments to treat cardiovascular problems.

The fastest-growing section is bioresorbable stents, which have the advantage of dissolving over time, lowering long-term problems such restenosis and thrombosis. Bioresorbable stents are rapidly gaining popularity in both developed and emerging economies, owing to continued advances in material science and an increasing preference for least invasive, temporary solutions.

Will Rising Demand for Drug-Coated Stents Fuel the Vascular Stents Market?

The increasing demand for drug-coated stents is projected to drive the vascular stents market. Drug-coated stents, also known as drug-eluting stents, are extremely efficient at reducing restenosis (re-narrowing of arteries) and have become the preferred treatment option for coronary artery disorders. This rising demand is being driven by the superior clinical outcomes that these stents give over bare-metal alternatives, making them indispensable in minimally invasive operations. In July 2024, the FDA approved Abbott's new, enhanced drug-coated stents, which aim to improve long-term results for patients with complicated cardiovascular problems. Meanwhile, in March 2024, the European Medicines Agency issued new rules to speed the clearance procedure for emerging stent technologies, including drug-coated stents, which are expected to boost their global acceptance these developments emphasize the expanding role of drug-coated stents in defining the future of vascular therapy.

Biodegradable coated stents are the fastest-growing class, as they combine the advantages of drug-eluting stents with coatings that disintegrate over time. These stents lessen long-term difficulties and the need for permanent implants, making them more appealing as biodegradable materials develop.

Country/Region-wise

Will Rising Advanced Healthcare Infrastructure in North America Drive the Vascular Stents Market?

The vascular stents market in North America is expected to increase significantly, owing to the region's rapidly improving healthcare infrastructure. As hospitals and medical centers invest in cutting-edge equipment and technology, the use of minimally invasive procedures, such as vascular stenting, is increasing. This tendency is aided by an aging population and rising prevalence of cardiovascular disorders. According to Verified Market Research, the vascular stents market is predicted to reach USD 9.38 Billion by 2023, rising at a 5.47% CAGR from 2023-2031. The market's growth is also aided by ongoing R&D activities, which result in the launched of more advanced and effective stent technologies.

In August 2024, the United States government provided more funds to expand cardiovascular care infrastructure as part of its healthcare reform projects, with an emphasis on improving access to modern medical treatments such as stenting. In May 2024, Boston Scientific announced the expansion of its vascular stents product line in the United States, highlighting the growing demand for advanced stent technologies, such as drug-eluting and bioresorbable stents, in response to the rising prevalence of cardiovascular disease. These improvements are projected to boost the vascular stents market in North America.

Will Rising Demand for Minimally Invasive Procedures in Asia Pacific Propel the Vascular Stents Market?

The Asia Pacific area is seeing an increase in demand for minimally invasive procedures, which is projected to enhance the vascular stents market. This trend is being driven by reasons such as rising cardiovascular disease prevalence, an aging population, and rising healthcare spending in nations such as China, India, and Japan. The demand for minimally invasive procedures over standard open surgeries is growing due to advantages such as faster recovery times, shorter hospital stays, and lower risk of problems. In January 2024, the Indian Ministry of Health and Family Welfare announced a new plan to increase access to sophisticated cardiac care, which includes funding for vascular stent treatments in public hospitals. This approach is intended to expand the use of stents among low-income individuals.

In April 2024, Medtronic announced plans to increase production of vascular stents in China, citing the growing demand for minimally invasive procedures. These investments and government support are expected to drive the adoption of vascular stents, making Asia Pacific one of the fastest-growing regions in this market.

Competitive Landscape

The competitive landscape of the vascular stents market is shaped by intense competition driven by innovation, technological advancements, and the growing demand for minimally invasive procedures. Smaller companies and regional players are increasingly entering the market, offering cost-effective alternatives and focusing on niche areas like bioresorbable stents or drug-eluting stents. In addition, strategic collaborations, mergers, and acquisitions are common as companies seek to enhance their product portfolios and expand their geographic reach. Regulatory approvals and compliance with healthcare standards also play a critical role, creating competitive advantages for companies that can navigate these processes effectively.

Some of the prominent players operating in the vascular stents market include:

Medtronic plc

Abbott Laboratories

Boston Scientific Corporation

Cook Medical, Inc.

Terumo Corporation

Cardinal Health, Inc.

Braun Melsungen AG

R. Bard, Inc.

MicroPort Scientific Corporation

Endologix, Inc.

Latest Developments

In April 2024, the business debuted a new drug-coated peripheral stent in the Asia Pacific region, with the goal of enhancing treatment outcomes for patients with peripheral artery disease, particularly in diabetic populations.

In March 2024, Terumo launched its next-generation bioresorbable stent in Japan, which dissolves over time to reduce long-term issues including thrombosis and promote natural channel repair.

In February 2024, BIOTRONIK increased their offering with the Orsiro Mission, a drug-eluting stent aimed to improve performance in treating coronary artery blockages. The device has acquired CE clearance and is slated to spread into European markets.